| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | CRSP | Common Shares | Options Exercise | +3,825 | +6.9% | 59,284 | 18 Feb 2024 | Direct | F1, F2 | ||
| transaction | CRSP | Common Shares | Sale | $152,409 | -1,913 | -3.2% | $79.67 | 57,371 | 20 Feb 2024 | Direct | F3 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | CRSP | Restricted Stock Units | Options Exercise | -3,825 | -33% | 7,650 | 18 Feb 2024 | Common Shares | 3,825 | Direct | F1, F4 |
| Id | Content |
|---|---|
| F1 | Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. |
| F2 | Includes 615 shares acquired under the CRISPR Therapeutics AG 2016 Employee Stock Purchase Plan. |
| F3 | Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. |
| F4 | This restricted stock unit award was granted on February 18, 2022 with respect to 15,300 Common Shares, with (i) one quarter of the shares vesting on February 18, 2023, (ii) one quarter of the shares vesting on February 18, 2024, (iii) one quarter of the shares vesting on February 18, 2025, and (iv) one quarter of the shares vesting on February 18, 2026. |